Show simple item record

dc.contributor.authorBrillante, Divina Gracilla
dc.contributor.authorO'Sullivan, Anthony John
dc.contributor.authorBrillante, Ruby Esmeralda
dc.contributor.authorHowes, Laurence Guy
dc.date.accessioned2017-05-03T14:18:31Z
dc.date.available2017-05-03T14:18:31Z
dc.date.issued2009
dc.identifier.issn0803-7051
dc.identifier.doi10.1080/08037050902982284
dc.identifier.urihttp://hdl.handle.net/10072/28580
dc.description.abstractBackground. There is evidence that in the early stages of type II diabetes, the cardiovascular system compensates by increasing endothelial nitric oxide synthase (e-NOS) expression. In the advanced stages of disease, e-NOS is diminished, and is associated with endothelial dysfunction. Angiotensin II, acting via the angiotensin II type 1 (AT1) receptor, is central to the development of endothelial dysfunction. The effect of AT1 receptor blockade on NOS expression and activity in humans with early insulin resistance syndrome (INSR) has not been previously investigated. Eight subjects with INSR participated in a randomized, double-blind, placebo-controlled, crossover study. Subjects were randomized to receive telmisartan or placebo (1 month of each) in a two-period crossover study with a 1-week washout period in between. The arterial stiffness and haemodynamic response to intravenous L-nitro-monomethyl arginine (L-NMMA 3mg/kg) was assessed at baseline and at the end of each treatment phase. SI (Stiffness index, a measure of large artery stiffness) and RI (Reflection index, small- to medium-sized arterial stiffness) were measured using digital photoplethysmography. Haemodynamic parameters [Heart rate (HR), Systolic blood pressure (SBP), Diastolic BP (DBP) and systemic vascular resistance index (SVRI)] were measured non-invasively using trans-thoracic bioimpedance. Results. Telmisartan significantly reduced baseline SI, SBP, DBP and SVRI. Infusion of L-NMMA produced a significant increase in RI and a significant reduction in HR during placebo therapy. Telmisartan therapy attenuated these responses. Conclusion. Telmisartan therapy reduced NOS activity and/or expression in these subjects, possibly because of improved vascular function arising from AT1 receptor blockade.
dc.description.peerreviewedYes
dc.description.publicationstatusYes
dc.languageEnglish
dc.language.isoeng
dc.publisherInforma Healthcare
dc.publisher.placeUnited Kingdom
dc.relation.ispartofstudentpublicationN
dc.relation.ispartofpagefrom142
dc.relation.ispartofpageto148
dc.relation.ispartofissue3
dc.relation.ispartofjournalBlood Pressure
dc.relation.ispartofvolume18
dc.rights.retentionY
dc.subject.fieldofresearchClinical sciences
dc.subject.fieldofresearchcode3202
dc.titleEffects of cardiovascular angiotensin II type 1 receptor blockade on nitric oxide synthase inhibition in patients with insulin resistance syndrome
dc.typeJournal article
dc.type.descriptionC1 - Articles
dc.type.codeC - Journal Articles
gro.date.issued2015-06-12T05:01:30Z
gro.hasfulltextNo Full Text
gro.griffith.authorHowes, Laurence G.


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record